Envisia is a biotechnology company that licensed technology from Liquidia Technologies and is focused on the development of novel ocular therapies by leveraging the unique and powerful properties of the PRINT® platform. The company’s lead program, ENV515, is a novel extended-release formulation of a prostaglandin analogue for the treatment of glaucoma. It has the potential to offer glaucoma patients an innovative product that can provide sustained reduction in IOP over many months after a single administration.
Research Triangle Park, NC
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.